New T1 classification

Area of Science:

• Oncology
• Thoracic Surgery
• Pathology

Background:

• The International Association for the Study of Lung Cancer (IASLC) staging committee revised descriptors for the 8th edition of the TNM staging system for lung cancer.
• Previous staging systems lacked granularity for small tumors and specific early-stage adenocarcinoma subtypes.

Purpose of the Study:

• To detail the modifications in the T descriptors for the 8th edition of lung cancer staging.
• To discuss the implications of these staging revisions on clinical practice and patient management.

Main Methods:

• Review of the proposed changes by the IASLC Staging and Prognostic Factor Committee for the 8th edition TNM staging.
• Analysis of the subclassification of T1 tumors into T1a, T1b, and T1c based on size.
• Inclusion of pathological entities like Adenocarcinoma-In-Situ (AIS) and Minimally Invasive Adenocarcinoma in the T descriptor framework.

Main Results:

• T1 tumors are now subclassified: T1a (<1 cm), T1b (>1 to <2 cm), and T1c (>2 to <3 cm).
• New stage groupings are introduced: T1aN0M0 is Stage IA1, T1bN0M0 is Stage IA2, and T1cN0M0 is Stage IA3.
• Adenocarcinoma-In-Situ (AIS) is coded as Tis, and Minimally Invasive Adenocarcinoma as T1a(mi).

Conclusions:

• The 8th edition TNM staging for lung cancer provides more precise classification for early-stage tumors.
• These updates aim to improve prognostic accuracy and guide treatment decisions for lung adenocarcinoma.
• Understanding these changes is crucial for oncologists, surgeons, and pathologists in managing lung cancer patients.